Peerbridge Health has announced the launch of its landmark COR-INSIGHT Trial, which will validate the screening and diagnostic capabilities of its Peerbridge Cor® ambulatory ECG wearables. The trial seeks to revolutionize cardiovascular and cardiopulmonary monitoring and screening by providing a seamless, non-invasive alternative to traditional diagnostic modalities. The trial will leverage two new proprietary, cutting-edge AI SaMD platforms: CardioMIND, an ECG+ analytical pipeline for cardiovascular indications and sleep disorder; and CardioQSync, a quantum-resonance based approach for extraction of cardiopulmonary and hemodynamic indications from respiratory ECG.
The trial is the first to prospectively evaluate multiplexed on-demand diagnostics directly from continuous ECG in hospital and home settings, integrating data-rich metrics for 30+ different indications. The American Heart Association statistical estimates place over 160 million adult Americans at risks for the indications being validated in this trial. The conditions range from previously announced ejection fraction severity, heart failure and sleep apnea diagnostics to more advanced cardiopulmonary insights and hemodynamic measurements, including cardiac output and stroke volume. By eliminating the reliance on imaging, catheter-based techniques, and biochemical assays, COR-INSIGHT promises a paradigm shift in diagnostic precision and accessibility from a single low-burden Cor ECG wearable.
"This trial represents an exciting leap forward in inexpensive, remote patient care," said Chris Darland, CEO of Peerbridge Health. "The Cor Insight trial allows us to provide over 30 cardiac and cardiopulmonary indications all from one simple wearable ECG study. Just as important as the clinical innovation is our ability to deliver these insights to clinicians at ultra-low cost. Bringing inexpensive hospital grade diagnostics to a patient's doorstep is a critical first step to reaching tens of millions of underserved patients and communities today."
Expanding Accessibility Across Care Settings
The COR-INSIGHT trial underscores the versatility of the Peerbridge Cor wearable, which aims to cater to patients across the clinical spectrum—from asymptomatic individuals to critically ill patients and those awaiting procedures like TAVR or ICD placement. The trial is designed to provide the monitoring in diverse settings, including outpatient, in-hospital, and home environments.
